Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aerpio Pharmaceuticals Inc    ARPO

AERPIO PHARMACEUTICALS INC

(ARPO)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/10/2019 06/11/2019 06/12/2019 06/13/2019 06/14/2019 Date
0.9803(c) 0.9905(c) 0.9751(c) 0.98(c) 0.97(c) Last
632 554 125 091 119 838 34 079 52 535 Volume
-1.97% +1.04% -1.55% +0.50% -1.02% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -29,8 M
Net income 2019 -29,1 M
Finance 2019 63,0 M
Yield 2019 -
Sales 2020 2,50 M
EBIT 2020 -26,9 M
Net income 2020 -26,8 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 0
Capi. / Sales2020 16,2x
Capitalization 40,6 M
More Financials
Company
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which... 
More about the company
Surperformance© ratings of Aerpio Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on AERPIO PHARMACEUTICALS INC
06/11AERPIO PHARMACEUTICALS : Initiates Phase 1b Clinical Trial of Topical Ocular For..
AQ
06/10AERPIO PHARMACEUTICALS : Initiates Phase 1b Clinical Trial of Topical Ocular For..
BU
05/16AERPIO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Other ..
AQ
05/09AERPIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
05/09AERPIO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fi..
AQ
05/09AERPIO PHARMACEUTICALS : Reports First Quarter 2019 Financial Results and Provid..
BU
05/03AERPIO PHARMACEUTICALS : Presents Data Showing Potential of AKB-9778, a VE-PTP I..
AQ
05/02AERPIO PHARMACEUTICALS : Presents Data Showing Potential of AKB-9778, a VE-PTP I..
BU
04/27AERPIO PHARMACEUTICALS : to Present Data Demonstrating Role of VE-PTP in Convent..
AQ
04/26AERPIO PHARMACEUTICALS : to Present Data Demonstrating Role of VE-PTP in Convent..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/14REGENERON PHARMACEUTICALS : Says Early-Stage Results Positive for REGN1979 in Ly..
DJ
06/13GSK signs up gene-editing pioneers in drug discovery alliance
RE
06/11GENMAB : J&J's Janssen in Pact for HexaBody-CD38 License
DJ
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
More sector news : Bio Therapeutic Drugs
Chart AERPIO PHARMACEUTICALS INC
Duration : Period :
Aerpio Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AERPIO PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 3,50 $
Spread / Average Target 250%
EPS Revisions
Managers
NameTitle
Stephen J. Hoffman Chief Executive Officer & Director
Joseph H. Gardner President & Director
Muneer A. Satter Chairman
Michael W. Rogers Chief Financial & Accounting Officer
Kevin Patrick Peters Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
AERPIO PHARMACEUTICALS INC-42.94%42
GILEAD SCIENCES6.09%80 909
VERTEX PHARMACEUTICALS2.72%42 680
REGENERON PHARMACEUTICALS-18.28%32 744
GENMAB10.45%10 857
SAREPTA THERAPEUTICS INC9.57%8 523